Biosig Technologies (NASDAQ:STEX) Upgraded at Wall Street Zen

Biosig Technologies (NASDAQ:STEX) was upgraded by investment analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a report released on Saturday.

Other research analysts have also recently issued reports about the stock. Needham & Company LLC decreased their target price on shares of Biosig Technologies from $9.00 to $8.00 and set a “buy” rating for the company in a report on Thursday, May 21st. Weiss Ratings raised Biosig Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 1st. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $8.00.

Biosig Technologies Price Performance

STEX opened at $0.92 on Friday. The stock has a fifty day moving average price of $1.06. Biosig Technologies has a one year low of $0.70 and a one year high of $14.11. The company has a market cap of $166.46 million, a P/E ratio of -0.09 and a beta of 1.85.

Biosig Technologies (NASDAQ:STEX) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.27) earnings per share for the quarter.

Insider Transactions at Biosig Technologies

In other Biosig Technologies news, CIO Mitchell Young Williams sold 263,863 shares of the business’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $0.79, for a total value of $208,451.77. Following the sale, the executive owned 3,037,648 shares of the company’s stock, valued at $2,399,741.92. The trade was a 7.99% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Karl Henry Michael Mcphie sold 30,611 shares of the stock in a transaction that occurred on Tuesday, April 14th. The stock was sold at an average price of $1.07, for a total value of $32,753.77. Following the completion of the transaction, the chief executive officer directly owned 969,389 shares of the company’s stock, valued at approximately $1,037,246.23. The trade was a 3.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have purchased 231,000 shares of company stock worth $252,360 and have sold 344,546 shares worth $294,660. Insiders own 52.73% of the company’s stock.

About Biosig Technologies

Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.

Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.